Retinal implant

Last updated
Diagram of the eye, the retina, and location of the various retinal implants. Retinal layers, from bottom to top: retinal pigment epithelium (RPE), photoreceptors (PR), horizontal cells (HC), bipolar cells (BC), amacrine cells (AC), ganglion cells (RGC), nerve fiber layer (RNFL). Diagram of the eye and placement of the retinal implants.jpg
Diagram of the eye, the retina, and location of the various retinal implants. Retinal layers, from bottom to top: retinal pigment epithelium (RPE), photoreceptors (PR), horizontal cells (HC), bipolar cells (BC), amacrine cells (AC), ganglion cells (RGC), nerve fiber layer (RNFL).

A retinal implant is a visual prosthesis for restoration of sight to patients blinded by retinal degeneration. The system is meant to partially restore useful vision to those who have lost their photoreceptors due to retinal diseases such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD). Retinal implants are being developed by a number of private companies and research institutions, and three types are in clinical trials: epiretinal (on the retina), subretinal (behind the retina), and suprachoroidal (between the choroid and the sclera). The implants introduce visual information into the retina by electrically stimulating the surviving retinal neurons. So far, elicited percepts had rather low resolution, and may be suitable for light perception and recognition of simple objects.

Contents

History

Foerster was the first to discover that electrical stimulation of the occipital cortex could be used to create visual percepts, phosphenes. [1] The first application of an implantable stimulator for vision restoration was developed by Drs. Brindley and Lewin in 1968. [2] This experiment demonstrated the viability of creating visual percepts using direct electrical stimulation, and it motivated the development of several other implantable devices for stimulation of the visual pathway, including retinal implants. [3] Retinal stimulation devices, in particular, have become a focus of research as approximately half of all cases of blindness are caused by retinal damage. [4] The development of retinal implants has also been motivated in part by the advancement and success of cochlear implants, which has demonstrated that humans can regain significant sensory function with limited input. [5]

The Argus II retinal implant, manufactured by Second Sight Medical Products received market approval in the US in Feb 2013 and in Europe in Feb 2011, becoming the first approved implant. [6] The device may help adults with RP who have lost the ability to perceive shapes and movement to be more mobile and to perform day-to-day activities. The epiretinal device is known as the Retina Implant and was originally developed in Germany by Retina Implant AG. It completed a multi-centre clinical trial in Europe and was awarded a CE Mark in 2013, making it the first wireless epiretinal electronic device to gain approval.

Candidates

Optimal candidates for retinal implants have retinal diseases, such as retinitis pigmentosa or age-related macular degeneration. These diseases cause blindness by affecting the photoreceptor cells in the outer layer of the retina, while leaving the inner and middle retinal layers intact. [4] [7] [8] [9] [10] [11] Minimally, a patient must have an intact ganglion cell layer in order to be a candidate for a retinal implant. This can be assessed non-invasively using optical coherence tomography (OCT) imaging. [12] Other factors, including the amount of residual vision, overall health, and family commitment to rehabilitation, are also considered when determining candidates for retinal implants. In subjects with age-related macular degeneration, who may have intact peripheral vision, retinal implants could result in a hybrid form of vision. In this case the implant would supplement the remaining peripheral vision with central vision information. [13]

Types

There are two main types of retinal implants by placement. Epiretinal implants are placed in the internal surface of the retina, while subretinal implants are placed between the outer retinal layer and the retinal pigment epithelium.

Epiretinal implants

Design principles

Epiretinal implants are placed on top of the retinal surface, above the nerve fiber layer, directly stimulating ganglion cells and bypassing all other retinal layers. Array of electrodes is stabilized on the retina using micro tacks which penetrate into the sclera. Typically, external video camera on eyeglasses [3] acquires images and transmits processed video information to the stimulating electrodes via wireless telemetry. [13] An external transmitter is also required to provide power to the implant via radio-frequency induction coils or infrared lasers. The real-time image processing involves reducing the resolution, enhancing contrast, detecting the edges in the image and converting it into a spatio-temporal pattern of stimulation delivered to the electrode array on the retina. [4] [13] The majority of electronics can be incorporated into the associated external components, allowing for a smaller implant and simpler upgrades without additional surgery. [14] The external electronics provides full control over the image processing for each patient. [3]

Advantages

Epiretinal implants directly stimulate the retinal ganglion cells, thereby bypassing all other retinal layers. Therefore, in principle, epiretinal implants could provide visual perception to individuals even if all other retinal layers have been damaged.

Disadvantages

Since the nerve fiber layer has similar stimulation threshold to that of the retinal ganglion cells, axons passing under the epiretinal electrodes are stimulated, creating arcuate percepts, and thereby distorting the retinotopic map. So far, none of the epiretinal implants had light-sensitive pixels, and hence they rely on external camera for capturing the visual information. Therefore, unlike natural vision, eye movements do not shift the transmitted image on the retina, which creates a perception of the moving object when person with such an implant changes the direction of gaze. Therefore, patients with such implants are asked to not move their eyes, but rather scan the visual field with their head. Additionally, encoding visual information at the ganglion cell layer requires very sophisticated image processing techniques in order to account for various types of the retinal ganglion cells encoding different features of the image.

Clinical study

The first epiretinal implant, the ARGUS device, included a silicon platinum array with 16 electrodes. [13] The Phase I clinical trial of ARGUS began in 2002 by implanting six participants with the device. All patients reported gaining a perception of light and discrete phosphenes, with the visual function of some patients improving significantly over time. Future versions of the ARGUS device are being developed with increasingly dense electrode arrays, allowing for improved spatial resolution. The most recent ARGUS II device contains 60 electrodes, and a 200 electrode device is under development by ophthalmologists and engineers at the USC Eye Institute. [15] The ARGUS II device received marketing approval in February 2011 (CE Mark demonstrating safety and performance), and it is available in Germany, France, Italy, and UK. Interim results on 30 patients long term trials were published in Ophthalmology in 2012. [16] Argus II received approval from the US FDA on April 14, 2013 FDA Approval [ dead link ]. Another epiretinal device, the Learning Retinal Implant, has been developed by IIP technologies GmbH, and has begun to be evaluated in clinical trials. [13] A third epiretinal device, EPI-RET, has been developed and progressed to clinical testing in six patients. The EPI-RET device contains 25 electrodes and requires the crystalline lens to be replaced with a receiver chip. All subjects have demonstrated the ability to discriminate between different spatial and temporal patterns of stimulation. [17]

Subretinal implants

Design principles

Subretinal implants sit on the outer surface of the retina, between the photoreceptor layer and the retinal pigment epithelium, directly stimulating retinal cells and relying on the normal processing of the inner and middle retinal layers. [3] Adhering a subretinal implant in place is relatively simple, as the implant is mechanically constrained by the minimal distance between the outer retina and the retinal pigment epithelium. A subretinal implant consists of a silicon wafer containing light sensitive microphotodiodes, which generate signals directly from the incoming light. Incident light passing through the retina generates currents within the microphotodiodes, which directly inject the resultant current into the underlying retinal cells via arrays of microelectrodes. The pattern of microphotodiodes activated by incident light therefore stimulates a pattern of bipolar, horizontal, amacrine, and ganglion cells, leading to a visual perception representative of the original incident image. In principle, subretinal implants do not require any external hardware beyond the implanted microphotodiodes array. However, some subretinal implants require power from external circuitry to enhance the image signal. [4]

Advantages

A subretinal implant is advantageous over an epiretinal implant in part because of its simpler design. The light acquisition, processing, and stimulation are all carried out by microphotodiodes mounted onto a single chip, as opposed to the external camera, processing chip, and implanted electrode array associated with an epiretinal implant. [4] The subretinal placement is also more straightforward, as it places the stimulating array directly adjacent to the damaged photoreceptors. [3] [13] By relying on the function of the remaining retinal layers, subretinal implants allow for normal inner retinal processing, including amplification, thus resulting in an overall lower threshold for a visual response. [3] Additionally, subretinal implants enable subjects to use normal eye movements to shift their gaze. The retinotopic stimulation from subretinal implants is inherently more accurate, as the pattern of incident light on the microphotodiodes is a direct reflection of the desired image. Subretinal implants require minimal fixation, as the subretinal space is mechanically constrained and the retinal pigment epithelium creates negative pressure within the subretinal space. [4]

Disadvantages

The main disadvantage of subretinal implants is the lack of sufficient incident light to enable the microphotodiodes to generate adequate current. Thus, subretinal implants often incorporate an external power source to amplify the effect of incident light. [3] The compact nature of the subretinal space imposes significant size constraints on the implant. The close proximity between the implant and the retina also increases the possibility of thermal damage to the retina from heat generated by the implant. [4] Subretinal implants require intact inner and middle retinal layers, and therefore are not beneficial for retinal diseases extending beyond the outer photoreceptor layer. Additionally, photoreceptor loss can result in the formation of a membrane at the boundary of the damaged photoreceptors, which can impede stimulation and increase the stimulation threshold. [13]

Clinical studies

Optobionics was the first company to develop a subretinal implant and evaluate the design in a clinical trial. Initial reports indicated that the implantation procedure was safe, and all subjects reported some perception of light and mild improvement in visual function. [18] The current version of this device has been implanted in 10 patients, who have each reported improvements in the perception of visual details, including contrast, shape, and movement. [4] Retina Implant AG in Germany has also developed a subretinal implant, which has undergone clinical testing in nine patients. Trial was put on hold due to repeated failures. [13] The Retina Implant AG device contains 1500 microphotodiodes, allowing for increased spatial resolution, but requires an external power source. Retina implant AG reported 12 months results on the Alpha IMS study in February 2013 showing that six out of nine patients had a device failure in the nine months post implant Proceedings of the royal society B, and that five of the eight subjects reported various implant-mediated visual perceptions in daily life. One had optic nerve damage and did not perceive stimulation. The Boston Subretinal Implant Project has also developed several iterations of a functional subretinal implant, and focused on short term analysis of implant function. [19] Results from all clinical trials to date indicate that patients receiving subretinal implants report perception of phosphenes, with some gaining the ability to perform basic visual tasks, such as shape recognition and motion detection. [13]

Spatial resolution

The quality of vision expected from a retinal implant is largely based on the maximum spatial resolution of the implant. Current prototypes of retinal implants are capable of providing low resolution, pixelated images.

"State-of-the-art" retinal implants incorporate 60-100 channels, sufficient for basic object discrimination and recognition tasks. However, simulations of the resultant pixelated images assume that all electrodes on the implant are in contact with the desired retinal cell; in reality the expected spatial resolution is lower, as a few of the electrodes may not function optimally. [3] Tests of reading performance indicated that a 60-channel implant is sufficient to restore some reading ability, but only with significantly enlarged text. [20] Similar experiments evaluating room navigation ability with pixelated images demonstrated that 60 channels were sufficient for experienced subjects, while naïve subjects required 256 channels. This experiment, therefore, not only demonstrated the functionality provided by low resolution visual feedback, but also the ability for subjects to adapt and improve over time. [21] However, these experiments are based merely on simulations of low resolution vision in normal subjects, rather than clinical testing of implanted subjects. The number of electrodes necessary for reading or room navigation may differ in implanted subjects, and further testing needs to be conducted within this clinical population to determine the required spatial resolution for specific visual tasks.

Simulation results indicate that 600-1000 electrodes would be required to enable subjects to perform a wide variety of tasks, including reading, face recognition, and navigating around rooms. [3] Thus, the available spatial resolution of retinal implants needs to increase by a factor of 10, while remaining small enough to implant, to restore sufficient visual function for those tasks. It is worth to note high-density stimulation is not equal to high visual acuity (resolution), which requires a lot of factors in both hardware (electrodes and coatings) and software (stimulation strategies based on surgical results). [22]

Current status and future developments

Clinical reports to date have demonstrated mixed success, with all patients report at least some sensation of light from the electrodes, and a smaller proportion gaining more detailed visual function, such as identifying patterns of light and dark areas. The clinical reports indicate that, even with low resolution, retinal implants are potentially useful in providing crude vision to individuals who otherwise would not have any visual sensation. [13] However, clinical testing in implanted subjects is somewhat limited and the majority of spatial resolution simulation experiments have been conducted in normal controls. It remains unclear whether the low level vision provided by current retinal implants is sufficient to balance the risks associated with the surgical procedure, especially for subjects with intact peripheral vision. Several other aspects of retinal implants need to be addressed in future research, including the long term stability of the implants and the possibility of retinal neuron plasticity in response to prolonged stimulation. [4]

The Manchester Royal Infirmary and Prof Paulo E Stanga announced on July 22, 2015, the first successful implantation of Second Sight's Argus II in patients with severe Age Related Macular Degeneration. [23] [24] These results are very impressive as it appears that the patients integrate the residual vision and the artificial vision. It potentially opens the use of retinal implants to millions of patients with AMD.

See also

Related Research Articles

<span class="mw-page-title-main">Retina</span> Part of the eye

The retina is the innermost, light-sensitive layer of tissue of the eye of most vertebrates and some molluscs. The optics of the eye create a focused two-dimensional image of the visual world on the retina, which then processes that image within the retina and sends nerve impulses along the optic nerve to the visual cortex to create visual perception. The retina serves a function which is in many ways analogous to that of the film or image sensor in a camera.

<span class="mw-page-title-main">Retinitis pigmentosa</span> Gradual retinal degeneration leading to progressive sight loss

Retinitis pigmentosa (RP) is a genetic disorder of the eyes that causes loss of vision. Symptoms include trouble seeing at night and decreasing peripheral vision. As peripheral vision worsens, people may experience "tunnel vision". Complete blindness is uncommon. Onset of symptoms is generally gradual and often begins in childhood.

<span class="mw-page-title-main">Macular edema</span> Medical condition

Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye and causes it to thicken and swell (edema). The swelling may distort a person's central vision, because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail, form, and color that is directly in the centre of the field of view.

<span class="mw-page-title-main">Electroretinography</span>

Electroretinography measures the electrical responses of various cell types in the retina, including the photoreceptors, inner retinal cells, and the ganglion cells. Electrodes are placed on the surface of the cornea or on the skin beneath the eye to measure retinal responses. Retinal pigment epithelium (RPE) responses are measured with an EOG test with skin-contact electrodes placed near the canthi. During a recording, the patient's eyes are exposed to standardized stimuli and the resulting signal is displayed showing the time course of the signal's amplitude (voltage). Signals are very small, and typically are measured in microvolts or nanovolts. The ERG is composed of electrical potentials contributed by different cell types within the retina, and the stimulus conditions can elicit stronger response from certain components.

<span class="mw-page-title-main">Choroideremia</span> Medical condition

Choroideremia is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life. Progression continues throughout the individual's life, but both the rate of change and the degree of visual loss are variable among those affected, even within the same family.

Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.

<span class="mw-page-title-main">Retinal nerve fiber layer</span> Part of the eye

In the anatomy of the eye, the retinal nerve fiber layer (RNFL) or nerve fiber layer, stratum opticum, is formed by the expansion of the fibers of the optic nerve; it is thickest near the optic disc, gradually diminishing toward the ora serrata.

<span class="mw-page-title-main">Optic disc drusen</span> Medical condition

Optic disc drusen (ODD) are globules of mucoproteins and mucopolysaccharides that progressively calcify in the optic disc. They are thought to be the remnants of the axonal transport system of degenerated retinal ganglion cells. ODD have also been referred to as congenitally elevated or anomalous discs, pseudopapilledema, pseudoneuritis, buried disc drusen, and disc hyaline bodies.

<span class="mw-page-title-main">Epiretinal membrane</span> Eye disease

Epiretinal membrane or macular pucker is a disease of the eye in response to changes in the vitreous humor or more rarely, diabetes. Sometimes, as a result of immune system response to protect the retina, cells converge in the macular area as the vitreous ages and pulls away in posterior vitreous detachment (PVD).

A visual prosthesis, often referred to as a bionic eye, is an experimental visual device intended to restore functional vision in those with partial or total blindness. Many devices have been developed, usually modeled on the cochlear implant or bionic ear devices, a type of neural prosthesis in use since the mid-1980s. The idea of using electrical current to provide sight dates back to the 18th century, discussed by Benjamin Franklin, Tiberius Cavallo, and Charles LeRoy.

<span class="mw-page-title-main">Retinal degeneration (rhodopsin mutation)</span> Retinopathy

Retinal degeneration is a retinopathy which consists in the deterioration of the retina caused by the progressive death of its cells. There are several reasons for retinal degeneration, including artery or vein occlusion, diabetic retinopathy, R.L.F./R.O.P., or disease. These may present in many different ways such as impaired vision, night blindness, retinal detachment, light sensitivity, tunnel vision, and loss of peripheral vision to total loss of vision. Of the retinal degenerative diseases retinitis pigmentosa (RP) is a very important example.

Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness.

Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.

<span class="mw-page-title-main">Gholam A. Peyman</span> Iranian-American ophthalmologist and retina surgeon known for inventing LASIK eye surgery

Gholam A. Peyman is an Iranian American ophthalmologist, retina surgeon, and inventor. He is best known for his invention of LASIK eye surgery, a vision correction procedure designed to allow people to see clearly without glasses. He was awarded the first US patent for the procedure in 1989.

<span class="mw-page-title-main">Photovoltaic retinal prosthesis</span>

Photovoltaic retinal prosthesis is a technology for restoring sight to patients blinded by degenerative retinal diseases, such as retinitis pigmentosa and age-related macular degeneration (AMD), when patients lose the 'image capturing' photoreceptors, but neurons in the 'image-processing' inner retinal layers are relatively well-preserved. This subretinal prosthesis is designed to restore a patients' sight by electrically stimulating the surviving inner retinal neurons, primarily the bipolar cells. Photovoltaic retinal implants are completely wireless and powered by near-infrared illumination (880nm) projected from the augmented-reality glasses. Therefore, they do not require such complex surgical methods as needed for other retinal implants, which are powered via extraocular electronics connected to the retinal array by a trans-scleral cable. Optical activation of the photovoltaic pixels allows scaling the implants to thousands of electrodes.

<span class="mw-page-title-main">Argus retinal prosthesis</span>

Argus retinal prosthesis, also known as a bionic eye, is an electronic retinal implant manufactured by the American company Second Sight Medical Products. It is used as a visual prosthesis to improve the vision of people with severe cases of retinitis pigmentosa. The Argus II version of the system was approved for marketing in the European Union in March 2011, and it received approval in the US in February 2013 under a humanitarian device exemption. The Argus II system costs about US$150,000, excluding the cost of the implantation surgery and training to learn to use the device. Second Sight had its IPO in 2014 and was listed on Nasdaq.

José-Alain Sahel is a French ophthalmologist and scientist. He is currently the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Eye Center, and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute in Paris, a research center associated with the one of the oldest eye hospitals of Europe - Quinze-Vingts National Eye Hospital in Paris, founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies. He is a member of the French Academy of Sciences.

<span class="mw-page-title-main">Robert MacLaren</span> British ophthalmologist

Robert E. MacLaren FMedSci FRCOphth FRCS FACS VR is a British ophthalmologist who has led pioneering work in the treatment of blindness caused by diseases of the retina. He is Professor of Ophthalmology at the University of Oxford and Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology. He is a Consultant Ophthalmologist at the Oxford Eye Hospital. He is also an Honorary Consultant Vitreo-retinal Surgeon at the Moorfields Eye Hospital. MacLaren is an NIHR Senior Investigator, or lead researcher, for the speciality of Ophthalmology. In addition, he is a member of the research committee of Euretina: the European Society of Retina specialists, Fellow of Merton College, in Oxford and a Fellow of the Higher Education Academy.

Occult macular dystrophy (OMD) is a rare inherited degradation of the retina, characterized by progressive loss of function in the most sensitive part of the central retina (macula), the location of the highest concentration of light-sensitive cells (photoreceptors) but presenting no visible abnormality. "Occult" refers to the degradation in the fundus being difficult to discern. The disorder is called "dystrophy" instead of "degradation" to distinguish its genetic origin from other causes, such as age. OMD was first reported by Y. Miyake et al. in 1989.

<span class="mw-page-title-main">Peter Szurman</span> German ophthalmologist

Peter Szurman is a German ophthalmologist, scientist, and professor of ophthalmology in Sulzbach/Saar.

References

  1. ↑ O. Foerster (1929). "Beitrage zur Pathophysiologie der Sehbahn und der Sehsphare". Journal für Psychologie und Neurologie. 39: 463–85.
  2. ↑ G. Brindley; W. Lewin (1968). "The sensation produced by electrical stimulation of the visual cortex". Journal of Physiology. 196 (2): 479–93. doi:10.1113/jphysiol.1968.sp008519. PMC   1351724 . PMID   4871047.
  3. 1 2 3 4 5 6 7 8 9 J. Weiland; T. Liu; M. Humayun (2005). "Retinal prosthesis". Annual Review of Biomedical Engineering. 7: 361–401. doi:10.1146/annurev.bioeng.7.060804.100435. PMID   16004575.
  4. 1 2 3 4 5 6 7 8 9 E. Zrenner (2002). "Will retinal implants restore vision?". Science. 295 (5557): 1022–5. Bibcode:2002Sci...295.1022Z. doi:10.1126/science.1067996. PMID   11834821. S2CID   1561668.
  5. ↑ F. Zeng (2004). "Trends in cochlear implants". Trends in Amplification. 8 (1): 1–34. doi:10.1177/108471380400800102. PMC   4111484 . PMID   15247993.
  6. ↑ "FDA approves first retinal implant for adults with rare genetic eye disease". fda.gov. U.S. Food and Drug Administration. 14 February 2013. Retrieved 14 March 2015.
  7. ↑ J. Stone; W. Barlow; M. Humayun; E. deJuan Jr.; A. Milam (1992). "Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa". Archives of Ophthalmology. 110 (11): 1634–9. doi:10.1001/archopht.1992.01080230134038. PMID   1444925.
  8. ↑ A. Santos; M. Humayun; E. deJuan Jr.; R. Greenburg; M. Marsh; I. Klock; et al. (1997). "Preservation of the inner retina in retinitis pigmentosa: A morphometric analysis". Archives of Ophthalmology. 115 (4): 511–5. doi:10.1001/archopht.1997.01100150513011. PMID   9109761.
  9. ↑ M. Humayun (1999). "Morphometric analysis of the extra- macular retina from post mortem eyes with retinitis pigmentosa". Investigative Ophthalmology and Visual Science. 40 (1): 143–8. PMID   9888437.
  10. ↑ S. Kim; S. Sadda; M. Humayun; E. deJuan Jr.; B. Melia; W. Green (2002). "Morphometric analysis of the macula in eyes with geographic atrophy due to age-related macular degeneration". Retina. 46 (4): 4–10. doi:10.1097/00006982-200208000-00011. PMID   12172114. S2CID   42400320.
  11. ↑ S. Kim; S. Sadda; J. Pearlman; M. Humayun; E. deJuan Jr.; B. Melia; et al. (2002). "Morphometric analysis of the macula in eyes with disciform age-related macular degeneration". Retina. 47 (4): 471–477. doi:10.1097/00006982-200208000-00012. PMID   12172115. S2CID   25004245.
  12. ↑ T. Matsuo; N. Morimoto (2007). "Visual acuity and perimacular retinal layers detected by optical coherence tomography in patients with retinitis pigmentosa". Investigative Ophthalmology and Visual Science. 91 (7): 888–90. doi:10.1136/bjo.2007.114538. PMC   1955635 . PMID   17314147.
  13. 1 2 3 4 5 6 7 8 9 10 G. Chader; J. Weiland; M. Humayun (2009). "Artificial vision: Needs, functioning, and testing of a retinal electronic prosthesis". Neurotherapy: Progress in Restorative Neuroscience and Neurology. Progress in Brain Research. Vol. 175. pp. 0079–6123. doi:10.1016/s0079-6123(09)17522-2. ISBN   9780123745118. PMID   19660665.
  14. ↑ W. Liu; K. Vichienchom; M. Clements; C. Demarco; C. Hughes; C. McGucken; et al. (2000). "A neurostimulus chip with telemetry unit for retinal prosthesis device". IEEE Journal of Solid-State Circuits. 35 (10): 1487–97. Bibcode:2000IJSSC..35.1487L. doi:10.1109/4.871327. S2CID   32093349.
  15. ↑ M. Humayun; J. Weiland; G. Fujii; R. Greenberg; R. Williamson; J. Little; et al. (2003). "Visual perception in a blind subject with a chronic microelectronic retinal prosthesis". Vision Research. 43 (24): 2573–81. doi:10.1016/s0042-6989(03)00457-7. PMID   13129543.
  16. ↑ Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Eliott D, Filley E, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg RJ (2012). "Interim results from the international trial of Second Sight's visual prosthesis". Ophthalmology. 119 (4): 779–88. doi:10.1016/j.ophtha.2011.09.028. PMC   3319859 . PMID   22244176.
  17. ↑ S. Klauke; M. Goertz; S. Rein; D. Hoehl; U. Thomas; R. Eckhorn; F. Bremmer; T. Wachtler (2011). "Stimulation with a wireless intraocular epiretinal implant elicits visual percepts in blind humans". Investigative Ophthalmology and Visual Science. 52 (1): 449–55. doi:10.1167/iovs.09-4410. PMID   20861492.
  18. ↑ A. Chow; V. Chow; K. Packo; J. Pollack; G. Peyman; R. Schuchard (2004). "The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa". Archives of Ophthalmology. 122 (4): 1156–7. doi:10.1001/archopht.122.4.460. PMID   15078662.
  19. ↑ J. Rizzo III; J. Wyatt Jr.; J. Lowenstein; S. Kelly; D. Shire (2003). "Perceptual efficacy of electrical stimulation of human retina with micro electrode array during short- term surgical trials". Investigative Ophthalmology and Visual Science. 44 (12): 5362–5369. doi:10.1167/iovs.02-0817. PMID   14638739.
  20. ↑ A. Fornos; J. Sommerhalder; M. Pelizzone (2011). "Reading with a simulated 60-channel implant". Frontiers in Neuroscience. 5: 57. doi: 10.3389/fnins.2011.00057 . PMC   3089939 . PMID   21625622.
  21. ↑ G. Dagnelie; P. Keane; V. Narla; L. Yang; J. Weiland; M. Humayun (2007). "Real and virtual mobility performance in simulated prosthetic vision". Journal of Neural Engineering. 4 (1): S92-101. Bibcode:2007JNEng...4S..92D. doi:10.1088/1741-2560/4/1/s11. PMID   17325421. S2CID   28397414.
  22. ↑ Zeng, Q.; Zhao, S.; Yang, H.; Zhang, Y.; Wu, T. (2019-06-22). "Micro/Nano Technologies for High-Density Retinal Implant". Micromachines. Micromachines (Basel). 10 (6): 419. doi: 10.3390/mi10060419 . PMC   6630275 . PMID   31234507.
  23. ↑ Article in Times
  24. ↑ "Bionic eye implant world first". BBC News. 21 July 2015. Archived from the original on 2023-06-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.